Sarepta Therapeutics (Sarepta Therapeutics) Interest Expense

: $-22 Mil (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sarepta Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sarepta Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ 25 Mil. Sarepta Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -5 Mil. Sarepta Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 was 4.70. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sarepta Therapeutics Interest Expense Historical Data

The historical data trend for Sarepta Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-30.67

-59.95

-63.53

-53.25

-22.01

Sarepta Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-6.69	-6.32	-5.22	-5.23	-5.23

Sarepta Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22 Mil.

Sarepta Therapeutics (NAS:SRPT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sarepta Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-5 Mil. Its Operating Income for the three months ended in Dec. 2023 was $25 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1,273 Mil.

Sarepta Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	24.625	/	-5.234
	=	4.70

The higher the ratio, the stronger the company's financial strength is.

Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Executives

Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme	officer: Senior Vice President, CFO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901